NCT01634243View on ClinicalTrials.gov

A Dose-ranging Study for SPM 962 in Parkinson's Disease Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

May 31, 2006

Study Completion Date

May 31, 2006

Conditions
Parkinson's Disease
Interventions
DRUG

SPM 962

SPM 962 transdermal patch once a daily up to 36.0 mg/day

Trial Locations (5)

Unknown

Kanto Region

Kinki Region

Kyushu Region

Shikoku Region

Tohoku Region

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY